Speakers
Alejandro Amador
Head, Scientific Leader Discovery Biology Automation
GSK
Workshop B
July 16, 2019
11:30 am |
Introduction & Overview to 3D High Content Screening Approaches
Ana Zarubica
COO
Inserm Centre D’Immunoph- ENomique
Day Two
Thursday 13th December 2018
9:45 am | Q&A Panel - Strategy – Selection – Characterization
9:20 am | Immunoprofiling of Murine Tumor Models to Improve the Translational Prediction of Immune-Based Therapeutics
Andrew Rhim
Associate Director - Translational Research & Assistant Professor – Gastroenterology
MD Anderson Cancer Center
Chen Zhao
Clinical Fellow
National Institutes of Health
Corinne Reimer
Associate Director, In Vivo Pharmacology
AstraZeneca
Day One
Thursday 13th December 2018
5:20 pm | Q&A - Modelling Cancer Drug Resistance
4:30 pm | Translational Strategies to Overcome Primary, Acquired & Adaptive Resistance
Dan Powell
Director, Clinical Tumor Tissue Facility & Associate Professor
University of Pennsylvania
Day Two
Thursday 13th December 2018
9:45 am | Q&A Panel - Strategy – Selection – Characterization
8:55 am | Models to Understand the Mechanisms of Action of Cancer Biologic Therapies
Davy Ouyang
Executive Director
Crown Bioscience
Day One
Thursday 13th December 2018
10:10 am | Panel Discussion - The Changing Expectations of Model Requirements
8:55 am | Developing Human Target Knock-In Mouse Models for Immuno-Oncology Drug Discovery
Enrique Alvarez
Director - Preclinical Development
Kleo Pharmaceuticals Inc.
Esmaiel Jabbari
Professor
University of South Carolina
Workshop C
July 16, 2019
3:00 pm |
Considerations in Modelling the Microenvironment
Fangxian Sun
Lead Investigator - Research Pharmacology
Sanofi
Day Two
Thursday 13th December 2018
2:30 pm | Moderator Feedback Panel
Fred Roberts
Sales Manager
Fuji film Visual Sonics
Geeta Sharma
Scientific Fellow, Translational Research
Tesaro
Day Two
Thursday 13th December 2018
9:45 am | Q&A Panel - Strategy – Selection – Characterization
8:30 am | Providing Translational Support for TSR Programs
Hervé Luche
Scientific Director Immunophenotyping Unit
Inserm Centre D’Immunoph- ENomique
Day Two
Thursday 13th December 2018
9:45 am | Q&A Panel - Strategy – Selection – Characterization
9:20 am | Immunoprofiling of Murine Tumor Models to Improve the Translational Prediction of Immune-Based Therapeutics
Hongmin Chen
Principal Scientist
Merck
Day Two
Thursday 13th December 2018
2:30 pm | Moderator Feedback Panel
Jenni Bernoulli
COO
Pharmatest Services
Juan Delgado
Lead Data Scientist
Fuel3D
Keiji Furuuchi
Associate Director & Head of Immunotherapy & Preclinical Development
Eisai
Kerry Whalen
Director - Discovery & Translational Biology
Tarveda Therapeutics
Lindsey Crowley
Scientist EMD
Serono
Day Two
Thursday 13th December 2018
2:30 pm | Moderator Feedback Panel
Maryland Franklin
Vice President – Scientific Development
MI Bioresearch
Day One
Thursday 13th December 2018
4:05 pm | Syngeneic Models of Breast and Ovarian Cancers: Effects of Immune Modulatory Agents in Classically “Cold” Tumors
Mike Brehm
Professor
University of Massachusettes
Day One
Thursday 13th December 2018
10:10 am | Panel Discussion - The Changing Expectations of Model Requirements
9:20 am | Opportunities & Challenges in Utilizing Humanized Mice to Model Human T Cell Responses
Mithun Khattar
Scientist & Immuno- Oncology Lead
Takeda
Neil Michaud
Director, Translational Medicine
EpiZyme
Omid Ghasemi
Scientist I, Imaging
Takeda
Rhys Jones
Senior Director DMPK
Pfizer
Day Two
Thursday 13th December 2018
4:00 pm | Q&A Panel – Models Aiding Dose Translation and Understanding Drug Response
3:10 pm | Challenges & Opportunities in Understanding Drug Exposure at The Site Of Action Within Pre-Clinical Tumor Models And The Potential Implications Of Transporter Mediated Efflux
Rick Huntress
Director of Commercial Business Development
The Jackson Laboratory
Day One
Thursday 13th December 2018
10:10 am | Panel Discussion - The Changing Expectations of Model Requirements
9:45 am | Addressing the Demand for Clinically Relevant Models in IO Research
Sarah Knutsen
Director, Preclinical Biology
Twentyeight-Seven Therapeutics
Day Two
Thursday 13th December 2018
2:30 pm | Moderator Feedback Panel
Shanthi Ganesh
Associate Director
Dicerna Pharmaceuticals Corp.
Shiva Kazerounian
Principal Scientist, In Vivo Pharmacology Lead
Berg Pharma
Workshop A
July 16, 2019
8:00 am |
Challenges, Insights & Future Directions for Experimental Models in Cancer Immunotherapy
Shuxi Qiao
Senior Scientist Internal Medicine Research Unit
Pfizer Inc.
Silvia Goldoni
Investigator & Head of Oncology Lab
Novartis
Stefan Jellbauer
Technical Liaison for Translational Applications
Mitra Biotech
Day One
Thursday 13th December 2018
5:20 pm | Q&A - Modelling Cancer Drug Resistance
4:55 pm | A Clinically-Predictive Ex-Vivo Tumor Modeling Platform for Drug Discovery and Development
Tseten Jamling
VP of Research and Development
Hera Biolabs
Yvonne Evrard
Operations Manager
National Institute of Health Sciences
Day Two
Thursday 13th December 2018
4:00 pm | Q&A Panel – Models Aiding Dose Translation and Understanding Drug Response
3:35 pm | NCI’s Patient Derived Models Repository Quality Control and Preclinical Efforts
Daniel Gioeli
Associate Professor
University of Virginia
Natalia Malkova
Lab Head/ Principal Research Investigator
Sanofi
Natalia Malkova is a principal research investigator in In vivo Pharmacology Group at Sanofi. She received her Ph.D. degree in molecular biology from Engelhardt Institute of Molecular Biology, Russia. She then continued her postdoctoral training in immunology at California Institute of Technology. Interests include cancer immunotherapy, tumor mouse models for preclinical and translational research, tumor microenvironment.
Day One
Thursday 13th December 2018